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421data for the overall angina burden and its impact on
patients’ quality of life. These analyses of the effect
of ranolazine on quality of life measures have been
completed, and recently published (2).
The third question is whether we observed a
glucose- and HBA1c-lowering effect of ranolazine
in TERISA. The objective of TERISA was to pros-
pectively assess the antianginal effectiveness of
ranolazine in patients with T2DM, not its potential
glucose-lowering effect. Therefore, although HBA1c
values were collected at baseline for cohort charac-
terization, no repeat measurements of HBA1c were
obtained following randomization, and no inference
with regard to ranolazine-mediated lowering of HBA1c
can be made from this clinical trial. Notably, an
extensive phase 3 drug development program to
assess the potential glycometabolic effects of ranola-
zine in a rigorously controlled fashion is currently
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An Independent Predictor of
Congestive Heart FailureOpdahl et al. (1) recently reported some interesting
ﬁndings from the MESA (Multi-Ethnic Study of
Atherosclerosis) trial showing that elevated resting
heart rate (HR) was associated with increased risk for
incident heart failure (HF) during a 7-year follow-up.
Subjects in the top HR quartile had a more than
3-fold greater adjusted relative risk for incident HF
than subjects in the bottom HR quartile. The authors
are to be commended for their interesting analysis, but
when commenting on their ﬁndings, they did not take
into account the recent results of the VALUE (Valsar-
tan Antihypertensive Long-term Use Evaluation)
study (2) which made a more extensive analysis of the
HR–HF association in a larger sample (n ¼ 15,245 sub-
jects). Our analysis showed that both the baseline HR
and the HR values recorded after 1 year (in-trial HR)
were strong predictors of incident HF (2). In a multi-
variate Coxmodel, the hazard ratios for the highest HR
quintile were 2.48 (95% conﬁdence interval [CI]: 1.91
to 3.21) for baseline HR and 1.93 (95% CI: 1.45 to 2.55)
for in-trial HR, compared to the bottom HR quintile.
In their article, the MESA investigators claimed
that the association between elevated HR and inci-
dent HF may be explained by mechanisms other than
an underlying coronary artery disease because in
their study HR was not a predictor of coronary events
(1). However, this negative ﬁnding was probably due
to their study being underpowered to detect this
relationship because in the VALUE study we found
a signiﬁcant independent association between HR
and incident myocardial infarction (2). The hazard
ratios for the highest HR quintile were 1.48 (95%
CI: 1.15 to 1.90) for baseline HR and 1.38 (95% CI: 1.03
to 1.85) for in-trial HR.
As the MESA investigators stated in their article
(1), HR might not be a causative factor and the con-
nection between HR and HF could be explained by a
latent left ventricular dysfunction accompanied by a
compensatory increase in resting HR (3). To exclude
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422this possibility, in the VALUE study, we evaluated the
effect of baseline HR on incident HF occurring sepa-
rately in each year of the trial (2). If tachycardia were a
marker of subclinical congestive HF, a stronger asso-
ciation would be expected in the early phases of the
follow-up with an attenuation in later years. However,
the association between high HR and incident HF was
present throughout the trial and was signiﬁcant even
at the ﬁfth year.
To see whether this ﬁnding obtained in a hyper-
tensive sample also holds true within a general pop-
ulation, we encourage the MESA investigators to
analyze the predictive power of baseline HR by using
the same statistical procedure.*Paolo Palatini, MD
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15:3–17.REPLY: Resting Heart Rate: An Independent
Predictor of Congestive Heart FailureWe thank Drs. Palatini and Julius for their interest in
our recent work (1). Indeed, in the MESA (Multi-Ethnic
Study of Atherosclerosis) study, with participants
without cardiovascular disease (CV) at enrollment, we
found an increased risk for incident heart failure (HF)
among those with elevated resting heart rate (HR).
We appreciate that in the VALUE (Valsartan Antihy-
pertensive Long-term Use Evaluation) trial extensive
analyses of resting HR and incident HF were made in a
large sample of hypertensive patients with high car-
diovascular risk on antihypertensive treatment (2).
Unfortunately, in-trial HR measurements were not a
part of our study (1).
We agree that a possible relationship between HR
and coronary events may have been unrecognized in
our study due to power issues. On the other hand, thisdoes not prove the existence of such a relationship in a
population without clinical CV diseases at enrollment,
and alternative mechanisms may also contribute or
coexist. Moreover, in our study, the resting HRs were
somewhat lower than in the hypertensive patients
in the VALUE trial, probably reﬂecting a healthier
population.
Using a statistical procedure similar to that in the
VALUE trial, we evaluated the effect of baseline HR
on HF events occurring separately for each 2-year
interval of follow-up. In this post hoc analysis, a sig-
niﬁcant association was found between resting HR
and HF events occurring during the ﬁrst 2-year
follow-up interval. In a multivariate Cox model, the
hazard ratio (HR) for the highest baseline HR quartile
(HR >70 beats/min) was 2.37 (95% conﬁdence inter-
val: 1.13 to 5.01) compared to the 3 lower quartiles
(HR <70 beats/min). However, no signiﬁcant associ-
ations were found between HR and HF events
occurring after the ﬁrst 2 years. Thus, in contrast to
the hypertensive sample in the VALUE study, in our
study population without CV disease at baseline, one
cannot exclude the possible relationship between
latent left ventricular dysfunction and elevated HF.
More studies of the relationship between resting HR
and CV disease are certainly needed and we thank
you for your valuable contributions to this ﬁeld.Anders Opdahl, MD, PhD
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